To determine whether the MTM-A analogues were able to interfere with the activity of Sp TFs in vivo upon systemic administration, mice bearing PC3 tumor xenografts were treated with a single IV injection of MTM-SDK (1.2 mg/kg), MTM-SK (8 mg/kg) or saline solution. This evidence concerns the gene MT1DP and neoplasm.